Open Access

CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients

  • Authors:
    • Huda Al Sayed Ahmed
    • Wasim Fawzi Raslan
    • Abdel Halim Salem Deifalla
    • Mohammad Dahmani Fathallah
  • View Affiliations

  • Published online on: April 24, 2019     https://doi.org/10.3892/mco.2019.1850
  • Pages: 67-76
  • Copyright: © Al Sayed Ahmed et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hodgkin's lymphoma (HL) is a hematological malignancy characterized by a minority of neoplastic cells outnumbered by tumor‑associated macrophages (TAMs). The overexpression of the CD163 antigen by TAMs is considered to be a significant predictive biomarker for risk stratification. This is likely caused by a genetic single‑nucleotide polymorphism (SNP) at the gene promoter. The aim of the present retrospective case‑control study was to establish a gene expression profile of a specific biomarker for classical HL (CHL) in order to predict the outcome and survival of CHL patients in Saudi Arabia. The protein expression of CD163 on TAMs was studied using immunohistochemistry (IHC). A prognosis index was calculated for the CD163 protein to assess the risk stratification of CHL. Genotyping of selected SNPs of this antigen was performed for 100 CHL cases and controls. The analysis revealed that the CD163 protein expression level was significantly correlated with disease relapse (DR) and overall survival (OS). In addition, the CD163 index threshold (15.0) was found to be significantly correlated with the relapse rate. Among the studied CD163 SNPs, rs75608120 exhibited a significant correlation with the DR rate of CHL patients, but not with OS. The findings of the present study confirmed that CD163 is a specific marker for TAMs, and its overexpression by TAMs is significantly associated with relapse and reduced survival post‑therapy. In addition, a new methodology of indexing CD163 protein expression for HL risk stratification was proposed. Thus, the present study identified a specific predictive molecular and antigenic biomarker for CHL prognosis.
View Figures
View References

Related Articles

Journal Cover

July 2019
Volume 11 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Al Sayed Ahmed, H., Raslan, W.F., Deifalla, A.H., & Fathallah, M.D. (2019). CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients. Molecular and Clinical Oncology, 11, 67-76. https://doi.org/10.3892/mco.2019.1850
MLA
Al Sayed Ahmed, H., Raslan, W. F., Deifalla, A. H., Fathallah, M. D."CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients". Molecular and Clinical Oncology 11.1 (2019): 67-76.
Chicago
Al Sayed Ahmed, H., Raslan, W. F., Deifalla, A. H., Fathallah, M. D."CD163 is a predictive biomarker for prognosis of classical Hodgkin's lymphoma in Saudi patients". Molecular and Clinical Oncology 11, no. 1 (2019): 67-76. https://doi.org/10.3892/mco.2019.1850